These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 12832228)

  • 1. Striatal glutamatergic mechanisms and extrapyramidal movement disorders.
    Chase TN; Bibbiani F; Oh JD
    Neurotox Res; 2003; 5(1-2):139-46. PubMed ID: 12832228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal plasticity and extrapyramidal motor dysfunction.
    Chase TN
    Parkinsonism Relat Disord; 2004 Jul; 10(5):305-13. PubMed ID: 15196510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms.
    Chase TN; Oh JD; Konitsiotis S
    J Neurol; 2000 Apr; 247 Suppl 2():II36-42. PubMed ID: 10991664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
    Marin C; Jimenez A; Bonastre M; Chase TN; Tolosa E
    Synapse; 2000 Jun; 36(4):267-74. PubMed ID: 10819904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
    Chase TN; Oh JD
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S122-9; discussion S129-30. PubMed ID: 10762139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neostriatal mechanisms in Parkinson's disease.
    Chase TN; Oh JD; Blanchet PJ
    Neurology; 1998 Aug; 51(2 Suppl 2):S30-5. PubMed ID: 9711978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic modulation of excitatory postsynaptic currents in rat neostriatal neurons.
    Umemiya M; Raymond LA
    J Neurophysiol; 1997 Sep; 78(3):1248-55. PubMed ID: 9310416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism.
    Chase TN; Oh JD
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S86-91. PubMed ID: 11052225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
    Oh JD; Chase TN
    Amino Acids; 2002; 23(1-3):133-9. PubMed ID: 12373527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New pharmacologic horizons in the treatment of Parkinson disease.
    Bonuccelli U; Del Dotto P
    Neurology; 2006 Oct; 67(7 Suppl 2):S30-8. PubMed ID: 17030738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease.
    Calabresi P; Centonze D; Pisani A; Sancesario G; Gubellini P; Marfia GA; Bernardi G
    Ann Neurol; 1998 May; 43(5):586-97. PubMed ID: 9585352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamatergic and GABAergic postsynaptic responses of striatal spiny neurons to intrastriatal and cortical stimulation recorded in slice preparations.
    Kita H
    Neuroscience; 1996 Feb; 70(4):925-40. PubMed ID: 8848174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological and molecular properties of AMPA/Kainate receptors expressed by striatal medium spiny neurons.
    Stefani A; Chen Q; Flores-Hernandez J; Jiao Y; Reiner A; Surmeier DJ
    Dev Neurosci; 1998; 20(2-3):242-52. PubMed ID: 9691198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPA receptor-dependent H2O2 generation in striatal medium spiny neurons but not dopamine axons: one source of a retrograde signal that can inhibit dopamine release.
    Avshalumov MV; Patel JC; Rice ME
    J Neurophysiol; 2008 Sep; 100(3):1590-601. PubMed ID: 18632893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic treatment weakens medium spiny neuron collateral inhibition in the parkinsonian striatum.
    Wei W; Ding S; Zhou FM
    J Neurophysiol; 2017 Mar; 117(3):987-999. PubMed ID: 27927785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homeostatic regulation of excitatory synapses on striatal medium spiny neurons expressing the D2 dopamine receptor.
    Thibault D; Giguère N; Loustalot F; Bourque MJ; Ducrot C; El Mestikawy S; Trudeau LÉ
    Brain Struct Funct; 2016 May; 221(4):2093-107. PubMed ID: 25782435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Perez XA; Zhang D; Bordia T; Quik M
    Mov Disord; 2017 Apr; 32(4):538-548. PubMed ID: 28256010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamatergic Innervation onto Striatal Neurons Potentiates GABAergic Synaptic Output.
    Paraskevopoulou F; Herman MA; Rosenmund C
    J Neurosci; 2019 Jun; 39(23):4448-4460. PubMed ID: 30936241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.